Dave & Buster's Entertainmen (PLAY) Stock Price Today—Real Time Charts and Quotes

Q: What are the 52-week high and low prices for Dave & Buster's Entertainmen (PLAY)?

PLAY has a 52-week high of $12.69 and a 52-week low of $11.52, with the current price at $12.62.

Q: What is the price-to-earnings (P/E) ratio of Dave & Buster's Entertainmen (PLAY)? What does it indicate?

The current P/E ratio (TTM) of PLAY is -13.832404517453798, indicating how much investors pay for each dollar of earnings. A higher P/E ratio often reflects stronger growth expectations, while a lower P/E ratio may suggest a more attractive valuation or slower growth. Comparing it with the average P/E of the Entertainment industry for a better context.

Q: What is the market cap of Dave & Buster's Entertainmen (PLAY)?

Dave & Buster's Entertainmen (PLAY) currently has a market cap of approximately $421.71M.

Q: What is the most recent quarterly earnings per share (EPS) for Dave & Buster's Entertainmen (PLAY)?

Dave & Buster's Entertainmen (PLAY)'s diluted earnings per share (Diluted EPS) is -1.4071510957324107. EPS = Net Income / Total Diluted Shares, which is a key metric for measuring a company's profitability.

Q: Should you buy or sell Dave & Buster's Entertainmen (PLAY) now?

As of now, PLAY is trading at $12.62, with a P/E ratio of -13.832404517453798 and a diluted EPS of -1.4071510957324107. Your buy or sell decisions should be based on your investment goals and risk tolerance. We recommend making an overall judgment by considering Dave & Buster's Entertainmen's financial reports, the outlook of the Entertainment sector, and your own holdings. Investing involves risk—please make decisions prudently.

Q: What factors can affect the stock price of Dave & Buster's Entertainmen (PLAY)?

Key factors include: company quarterly reports (revenue, EPS), competition and trends in the Entertainment sector, macroeconomic environment (interest rate, inflation), market sentiment, as well as major events like product releases and mergers & acquisitions.

Q: How to buy Dave & Buster's Entertainmen (PLAY) stock?

You can buy Dave & Buster's Entertainmen (PLAY) through Gate. Sign up for a Gate account and complete identity verification, then go to the Dave & Buster's Entertainmen trading page to make a purchase. Gate supports fractional share trading, so you can start investing without buying a whole share.

$12,62

+$0,31(+2,51%)

*Data last updated: 2026-04-08 04:07 (UTC+8)

As of 2026-04-08 04:07, Dave & Buster's Entertainmen (PLAY) is priced at $12,62, with a total market cap of $421,71M, a P/E ratio of -13,83, and a dividend yield of 0,00%. Today, the stock price fluctuated between $11,91 and $12,69. The current price is 5,96% above the day's low and 0,55% below the day's high, with a trading volume of 1,23M. Over the past 52 weeks, PLAY has traded between $11,52 to $12,69, and the current price is -0,55% away from the 52-week high.

PLAY Key Stats

Yesterday's Close$12,13

Market Cap$421,71M

Volume1,23M

P/E Ratio-13,83

Dividend Yield (TTM)0,00%

Dividend Amount$0,16

Diluted EPS (TTM)1,41

Net Income (FY)-$48,70M

Revenue (FY)$2,10B

Earnings Date2026-06-09

EPS Estimate0,67

Revenue Estimate$582,14M

Shares Outstanding34,76M

Beta (1Y)1.832

Ex-Dividend Date2020-01-09

Dividend Payment Date2020-02-10

About PLAY

Dave & Buster's Entertainment, Inc. owns and operates entertainment and dining venues for adults and families in North America. Its venues offer a menu of entrées and appetizers, as well as a selection of non-alcoholic and alcoholic beverages; and an assortment of entertainment attractions centered on playing games and watching live sports, and other televised events. The company operates its venues under the Dave & Buster's name. As of January 30, 2022, it owned and operated 144 stores located in 40 states, Puerto Rico, and one Canadian Province. The company was founded in 1982 and is headquartered in Coppell, Texas.

SectorCommunication Services

IndustryEntertainment

CEOTarun Lal

HeadquartersCoppell,TX,US

Official Websitehttps://ir.daveandbusters.com

Employees (FY)23,61K

Average Revenue (1Y)$89,06K

Net Income per Employee-$2,06K

Ulteriori informazioni su Dave & Buster's Entertainmen (PLAY)

Blogs

R2FtZXBsYXkgc3BpZWdhdG86IGNvbWUgZnVuemlvbmEgaWwgbW9kZWxsbyBQMkUgZGkgcHV6emxlIEFJIGRpIEEuSS5FYXJuIHN1IGFpIGVhcm4uY28=

YWkgZWFybi5jbyDDqCBjb211bmVtZW50ZSBjb25vc2NpdXRvIGNvbWUgQS5JLkVhcm4gKEFJRSk6IHVuIGNvbmNldHRvIFBsYXktdG8tRWFybiBiYXNhdG8gc3VsbOKAmWludGVsbGlnZW56YSBhcnRpZmljaWFsZSwgaW5jZW50cmF0byBzdWxsYSByaXNvbHV6aW9uZSBkaSBlbmlnbWkgZSBzZmlkZSBsb2dpY2hlLCBjb24gcmljb21wZW5zZSBjb2xsZWdhdGUgYWwgdG9rZW4gQUlFIHN1bGxhIEJOQiBTbWFydCBDaGFpbiAoQkVQLTIwKS4=

2026-01-08

QW5hbGlzaSBwacO5IHJlY2VudGUgZGVsIHByZXp6byBkZWwgdG9rZW4gUExBWTogaWwgcmVjZW50ZSB0cmVuZCByaWFsemlzdGEgY29udGludWVyw6A/

SW4gYXBwZW5hIHVuIG1lc2UsIGkgdG9rZW4gUExBWSBoYW5ubyByZWdpc3RyYXRvIHVu4oCZaW1wZW5uYXRhIGRpIHF1YXNpIGzigJk4MCUsIGF0dGlyYW5kbyBs4oCZYXR0ZW56aW9uZSBkaSB0dXR0byBpbCBtZXJjYXRvLiBNYSBzaSB0cmF0dGEgZGVsbOKAmWluaXppbyBkaSB1biBudW92byBtZXJjYXRvIHJpYWx6aXN0YSwgb3BwdXJlIMOoIHNvbG8gdW7igJlvbmRhdGEgZGkgZW50dXNpYXNtbyBkaSBicmV2ZSBkdXJhdGE/

2025-12-25

QW5hbGlzaSBkZWwgcHJvZ2V0dG8gUG93ZXIgUHJvdG9jb2wgKFBPV0VSKTogdW5hIHJpdm9sdXppb25lIG5lbGxlIGluZnJhc3RydXR0dXJlIGRlbCBzZXR0b3JlIEdhbWVGaQ==

SW4gdW4gbW9tZW50byBjcnVjaWFsZSBpbiBjdWkgaWwgc2V0dG9yZSBHYW1lRmkgc3RhIHBhc3NhbmRvIGRhaSBzZW1wbGljaSBtb2RlbGxpIHBsYXktdG8tZWFybiB2ZXJzbyBlc3BlcmllbnplIFNvY2lhbEdhbWVGaSA0LjAgc29zdGVuaWJpbGkgZSBhbHRhbWVudGUgY29pbnZvbGdlbnRpLCBQb3dlciBQcm90b2NvbCBzaSBzdGEgYWZmZXJtYW5kbyBjb21lIGlsIOKAnHNpc3RlbWEgb3BlcmF0aXZv4oCdIGRpIGJhc2UgcGVyIHF1ZXN0YSBudW92YSBlcmEu

2025-12-04

Dave & Buster's Entertainmen (PLAY) FAQ

What's the stock price of Dave & Buster's Entertainmen (PLAY) today?

Dave & Buster's Entertainmen (PLAY) is currently trading at $12,62, with a 24h change of +2,51%. The 52-week trading range is $11,52–$12,69.

What are the 52-week high and low prices for Dave & Buster's Entertainmen (PLAY)?

What is the price-to-earnings (P/E) ratio of Dave & Buster's Entertainmen (PLAY)? What does it indicate?

What is the market cap of Dave & Buster's Entertainmen (PLAY)?

What is the most recent quarterly earnings per share (EPS) for Dave & Buster's Entertainmen (PLAY)?

Should you buy or sell Dave & Buster's Entertainmen (PLAY) now?

What factors can affect the stock price of Dave & Buster's Entertainmen (PLAY)?

How to buy Dave & Buster's Entertainmen (PLAY) stock?

Risk Warning

The stock market involves a high level of risk and price volatility. The value of your investment may increase or decrease, and you may not recover the full amount invested. Past performance is not a reliable indicator of future results. Before making any investment decisions, you should carefully assess your investment experience, financial situation, investment objectives, and risk tolerance, and conduct your own research. Where appropriate, consult an independent financial adviser.

Disclaimer

The content on this page is provided for informational purposes only and does not constitute investment advice, financial advice, or trading recommendations. Gate shall not be held liable for any loss or damage resulting from such financial decisions. Further, take note that Gate may not be able to provide full service in certain markets and jurisdictions, including but not limited to the United States of America, Canada, Iran, and Cuba. For more information on Restricted Locations, please refer to the User Agreement.

Other Trading Markets

PLAY

CFD

Fai trading

Dave & Buster's Entertainmen (PLAY) Latest News

2026-04-03 07:20

NFT市场大洗牌：稀缺性失效，IP化与游戏转型决定谁能活到最后

Gate News 消息，NFT市场正经历深度重构，少数项目开始从投机资产转向可持续的品牌与知识产权（IP）运营模式。以Pudgy Penguins和Doodles为代表的项目，正通过零售、内容与AI扩展业务边界，其中Pudgy Penguins已实现超1300万美元销售额，显示出从链上资产向现实商业转化的能力。当前行业分化明显，单纯依赖稀缺性的NFT项目逐渐失去吸引力。CEX CEO Federico Variola指出，多数NFT尚未证明其在加密领域之外具备稳定变现能力，导致估值持续承压。而行业高管 Fernando Lillo Aranda则认为，市场已不再认可“稀缺性即价值”的逻辑，真正具备长期潜力的项目必须构建完整商业模式，并在零售、媒体或游戏领域建立用户需求。游戏赛道同样发生转向。早期“Play-to-Earn”模式因依赖新用户驱动而难以持续，当前逐步过渡至“Play-to-Own”，强调资产所有权与实际用途。8Blocks联合创始人 Anton Efimenko表示，这一变化降低了抛售压力，使玩家利益与生态长期发展更加一致。与此同时，NFT IP代币化成为新趋势。该模式提升流动性并扩大参与范围，但也带来治理分散与社区忠诚度下降的风险。随着投机资金进入，项目决策可能偏离长期发展目标，增加品牌运营难度。整体来看，NFT行业正进入筛选阶段。能够跨越加密周期、建立真实用户需求并形成商业闭环的项目更具生存空间，而依赖短期炒作的资产正逐步退出市场。未来，数字所有权能否在娱乐、文化及消费领域形成稳定价值，将成为NFT发展的关键变量。

2026-04-02 01:07

ARIA（Aria）24小时上涨25.33%

Gate News 消息，4 月 2 日，据 Gate 行情显示，截至发稿时，ARIA（Aria）现报 0.43 美元，24 小时内上涨 25.33%，最高触及 0.50 美元，最低回落至 0.33 美元，24 小时交易量达 162.39 万美元。当前市值约为 7794.7 万美元。 Aria.AI 是一项次世代游戏开发和发行实验，其灵感源自迪士尼式的沉浸式世界和 AI 技术，并以其自有 IP 相关的游戏玩法为核心进行设计。它代表着将 Web2 质量的游戏设计和发行标准（并结合 AI 执行）带入 Web3 时代的重大飞跃。作为一款开放世界手机游戏，Aria 邀请玩家探索 Fudonia 世界，通过 Play to Earn 机制赚取收益，并可铸造 ARIA Wishfont Pass 以加速排行榜晋升。该项目已获得包括 Folious Ventures、The Spartan Group、Merit Circle 等多家知名投资机构支持。此消息不作为投资建议，投资需注意市场波动风险。

2026-04-01 15:02

Hyperliquid 推出 Android 测试版 App，提醒用户警惕假冒应用

Gate News 消息，4 月 1 日，Hyperliquid 联创 iliensinc 在社群平台发文宣布，Hyperliquid 移动端应用已上线 Google Play Store。当前版本为 MVP 测试版，仅提供成交（fills）通知功能。该版本是从 PWA 向原生应用过渡的初步尝试，功能范围刻意精简，用于收集用户反馈并优化功能优先级及设备适配问题。测试阶段将限制下载数量。iliensinc 特别提醒用户避免下载 Play Store 中的假冒应用，建议通过官方渠道获取安装链接。后续版本将持续优化通知配置及功能体验。

2026-03-30 06:57

白宫App被曝疑似定位追踪！隐私风险与安全漏洞引争议

Gate News 消息，美国政府近期推出的一款官方应用程序正引发广泛关注。该应用旨在为用户提供接收政策更新、观看直播以及获取政府公告的渠道，但其潜在的数据收集与隐私风险问题迅速成为讨论焦点。部分开发者与安全研究人员指出，该应用可能涉及设备位置访问、网络活动记录及本地存储读取等权限请求。虽然这些功能在移动应用中较为常见，但由于该应用由政府推出，其数据使用范围与安全边界受到更严格审视。根据公开的隐私政策，该应用会自动记录用户IP地址等基础信息，同时在用户自愿提供的情况下收集姓名、电子邮件等数据。此外，Google Play 页面提及可能收集电话号码等个人信息，而苹果端则引导用户查看官方隐私条款。技术分析方面，开发者 Thereallo 与安全工程师 Adam 表示，在应用代码中发现与GPS定位相关的调用逻辑，理论上可实现周期性位置追踪。有说法称该功能可能每4.5分钟在前台触发一次定位请求，但目前尚未获得独立验证。研究人员强调，这类功能通常需要用户授权，但一旦启用即可持续运行。与此同时，安全层面的担忧同样存在。Adam 指出，在公共网络环境下，技术人员可能通过代理工具拦截数据流量，甚至对应用行为进行修改，反映出潜在的防护不足问题。尽管相关结论仍待进一步验证，此次事件已引发对政府应用数据透明度与隐私保护的广泛讨论。在数字化治理持续推进的背景下，用户对数据安全与权限管理的敏感度正在明显提升。

2026-03-22 11:16

黑客伪造 Google Play 商店页面，针对巴西用户实施加密货币挖矿与钱包劫持攻击

Gate News 消息，3 月 22 日，据 SecureList 披露，黑客近期通过仿冒 Google Play 商店的钓鱼页面，在巴西发起 Android 恶意软件攻击活动。目前所有已知受害者均位于巴西。攻击者搭建了与 Google Play 高度相似的钓鱼网站，诱导用户下载名为"INSS Reembolso"的伪造应用。该应用安装后，将分阶段释放隐藏恶意代码，并直接加载至内存运行，设备上不留可见文件，具有较强的隐蔽性。恶意软件的核心功能之一为加密货币挖矿，内置针对 ARM 设备编译的 XMRig 挖矿程序，可在后台静默连接攻击者控制的挖矿服务器。该程序会监控电池电量、温度及设备使用状态，动态调整挖矿行为以规避检测，并通过循环播放静音音频文件绕过 Android 系统的后台进程管理机制。部分变种还内置银行木马，可在某 CEX 和某钱包的 USDT 转账界面叠加伪造页面，静默替换收款地址。此外，恶意软件支持录音、截屏、键盘记录及远程锁机等多项远程控制指令。

Hot Posts su Dave & Buster's Entertainmen (PLAY)

gas_fee_therapy

1 minuti fa

Been thinking about the battery recycling space lately, and there's actually some solid opportunities emerging as EV adoption accelerates. With potentially 300 million electric vehicles on the road by 2030, the question of what happens to all those dead batteries becomes pretty critical. Most don't end up in landfills thankfully - instead they get processed to recover valuable materials like lithium, nickel, cobalt, and rare earth elements. Li-Cycle Holdings caught my attention recently. They're one of North America's leading lithium-ion battery recyclers and just ramped up operations in Germany with capacity to process 30,000 tonnes annually across their facility. The DOE backing them with a $375 million loan shows there's real institutional confidence here. This is exactly the kind of infrastructure play that makes sense as battery recycling stock investments start gaining traction. Then there's Umicore, operating recycling facilities across the U.S., China, Belgium, and Germany. What's interesting is they're diversified - catalysts, plating materials, plus recycling services. The battery recovery business could be a major margin driver for them going forward, especially as their other segments face headwinds. On the smaller side, RecycLiCo Battery Materials is positioning itself as a newer player. They're working on converting cathode scrap into black mass and eventually battery precursors. Got their demo plant running late 2022 and validation from a battery materials company in 2024. It's riskier but the upside potential is there if they execute. Ganfeng Lithium is huge - largest in China with operations spanning Africa, Australia, Argentina, Ireland, and Mexico. They've been quietly building out battery recycling capacity, including a project in Jiangxi province. When you've got that kind of scale and geographic reach, entering battery recycling stock territory is almost inevitable. American Battery Technology developed closed-loop recycling technology that separates and recovers critical materials from spent batteries. Their Nevada facility can handle 20,000 metric tonnes annually at full capacity. That kind of specialized infrastructure is valuable. Even Apple's getting serious about this - they're targeting 100% recycled cobalt in all their batteries by 2025, plus recycled rare earth elements in magnets and recycled materials in circuit boards. When major manufacturers commit to circular supply chains, it validates the entire battery recycling stock sector. BYD's partnership with Itochu since 2020 shows how this works in practice too - collecting spent EV batteries from their own vehicles and converting them into energy storage systems. As battery recycling becomes mainstream, this kind of vertical integration makes sense. The macro picture is clear: millions of batteries will need processing over the next few years, and the companies positioned in this space could see significant growth. Whether you're looking at established players like Umicore or growth-stage battery recycling stock names, the tailwinds are real.

TokenomicsTinfoilHat

2 minuti fa

Been following the genomics and synthetic biology space pretty closely lately, and there's something genuinely compelling happening here that more people should probably pay attention to. The fundamentals are solid, the market dynamics are shifting, and some of the companies operating in this sector look genuinely interesting from an investment perspective. Let me break down what's actually driving this. Genomics is essentially about understanding how all the genes in an organism work together, not just looking at individual genes in isolation. Over the past couple of decades, the cost of mapping someone's entire genome has dropped dramatically, the accuracy has improved, and the speed has accelerated. That combination has unlocked a whole new era in genetic medicine. Pharma and biotech companies are now using genomic information to understand how individual patients respond to specific drugs, which is opening doors to targeted therapies that were previously impossible. What's really interesting is how this connects to synthetic biology. Instead of just analyzing genes, synthetic biology takes engineering principles and applies them to biological systems. You're literally designing and building biological solutions. The applications span drug discovery, disease detection, enzyme engineering, gene editing, and basic research. The market opportunity here is substantial. Industry projections suggest the genomics market alone will hit around $157 billion by 2033, while the synthetic biology sector was valued at over $16 billion in 2024 and is expected to grow at roughly 17% annually through 2030. Those aren't small numbers. The real breakthrough came from two major directions. First, you've got companies like Illumina that pioneered sequencing technology. They built the infrastructure that made genomic analysis accessible and affordable. Then you've got the gene editing revolution, particularly CRISPR/Cas9 technology. That's where companies like BEAM Therapeutics and Intellia Therapeutics come in. They're using gene editing to actually correct genetic defects, not just identify them. Now, if you're actually looking at synthetic biology stocks worth considering, Twist Bioscience is one that stands out. They've developed a DNA synthesis platform that's genuinely disruptive. What makes them interesting is the breadth of what they're doing. They manufacture synthetic DNA-based products including synthetic genes, tools for next-generation sequencing, sample preparation kits, and antibody libraries for drug discovery. But they've expanded beyond just DNA into synthetic RNA and antibody proteins. They've got partnerships for biologic drug discovery and they're even exploring applications like digital data storage using synthetic DNA. That's creative thinking. The company serves biotech, pharma, industrial chemical companies, agricultural firms, and academic labs. Revenue grew 28% in 2024, driven by order growth in NGS tools and synthetic genes, and their guidance for 2025 looks solid. This is the kind of company that benefits directly from the secular tailwinds in genomics and synthetic biology stocks. Then there's Wave Life Sciences, which is operating at the clinical stage with a focus on RNA medicines. Their PRISM platform combines multiple modalities and chemistry innovation to target RNA for treating both rare and common disorders. They've got candidates in obesity, alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, and Huntington's disease. Their lead candidate WVE-007 is designed to target obesity through RNA silencing, and they've already completed enrollment in the first cohort of their clinical study. The company ended 2024 with over $300 million in cash, which gives them runway into 2027. That's meaningful because it means they have time to execute on their pipeline without immediate financing pressure. They're a different play than Twist, but they're positioned well in the synthetic biology stocks category. CRISPR Therapeutics is the third name worth highlighting. They're the company that achieved something genuinely historic in November 2023 when they got the first-ever approval for a CRISPR gene-edited therapy called Casgevy. That's not hype. That's an actual regulatory milestone for the sector. Casgevy is approved for sickle cell disease and transfusion-dependent beta thalassemia, both conditions with massive unmet medical needs. CRISPR is collaborating with Vertex Pharmaceuticals on this. But they're not stopping there. They're advancing multiple next-generation programs including CAR T candidates for various cancers and autoimmune diseases, plus they're working on stem cell-derived beta islet cells for type 1 diabetes. The company is essentially building a pipeline of gene-edited therapies across multiple indications. What ties all of this together is the underlying trend. We're at an inflection point where genomics has moved from being an academic exercise to being a practical tool for developing actual medicines. Synthetic biology stocks are benefiting because the fundamental economics have shifted. The tools are better, cheaper, and faster. The regulatory environment is starting to catch up with the science. Companies that built the infrastructure or are developing the therapies are positioned to capture value. The market opportunity is real. We're talking about transforming how medicine gets developed and deployed. That kind of structural shift doesn't happen often, and when it does, the companies positioned at the center of it tend to perform well over extended periods. If you're building a portfolio and you're looking at where innovation is actually driving returns, genomics and synthetic biology stocks deserve serious consideration. The data supports it, the pipeline supports it, and the regulatory environment is finally supporting it. That's a rare alignment.

tx_pending_forever

2 minuti fa

Been looking at some interesting opportunities in the Chinese semiconductor space lately. There's actually solid upside potential here if you understand the thesis. So here's the thing - most investors are fixated on US markets and Taiwan plays, but there's a whole segment of Chinese semiconductor stocks that could benefit from Beijing's push toward self-sufficiency. As the country ramps up domestic chip production, the companies positioned to capitalize on this shift could see real appreciation. Let me break down three names worth watching. First up is Hua Hong Semiconductor. This is one of China's main pure-play foundries, and they actually pulled off something pretty significant - a $2.6 billion listing on the Shanghai Stock Exchange back in 2023. That was China's biggest listing that year. What caught my attention is their specialty in 8-inch and 12-inch tech. As China moves to reduce reliance on Taiwan and external suppliers, a foundry like this becomes strategically important. The capital from that listing gives them room to expand, and I'd expect the stock to reflect that over time. Then there's Intchains Group. This one's more of a contrarian play - stock's down about 25% year-to-date and revenue took a hit in 2022. Not gonna sugarcoat it, the numbers look rough on the surface. But here's what makes it interesting: they've got $97 million in cash with only $1.9 million in liabilities. Recent losses were just $3.09 million. Plus, they grabbed assets from the Goldshell brand focused on Web3 infrastructure. So you've got a Chinese semiconductor play with blockchain exposure, trading cheap, and sitting on a solid balance sheet despite near-term headwinds. That's the kind of asymmetric bet some people are comfortable with. Last one is ACM Research. Unlike the others, this one's got near-term momentum. They revised their 2023 revenue guidance upward to $530-545 million, and they're guiding 2024 revenue at $650-725 million. Wall Street consensus is "Strong buy" with analysts targeting 23.5% upside. The backdrop is Chinese customers ramping up mature node capacity investments, and ACM's expanding their product lineup. Revenue expected to grow 40.6% with EPS up 139%. Obviously there's risk with all three - regulatory uncertainty, geopolitical factors, execution risk. But if you've got the risk tolerance, the reward potential in Chinese semiconductor stocks right now is legit worth exploring. The structural tailwinds from domestic chip production ambitions aren't going away anytime soon.

Prezzo Dave & Buster's Entertainmen

PLAY Key Stats

About PLAY

Trending